Preclinical experiments show that the drugs cepharanthine and nelfinavir may be effective treatments for COVID-19 While preventative care for COVID-19 has made much noise (with vaccines having rolled out in most countries), the soaring infection rates indicate the need for effective treatments. Using cultured cells to study SARS-CoV-2 infections, researchers at the Tokyo University of
Sickle cell disease is the most common deadly genetic disorder. It results from a mutation that causes normally pliable red blood cells to become brittle and sickle shaped. This leads to pain, organ damage and early death. A team of scientists led by Mitchell J. Weiss, MD, PhD, and Jonathan Yen, PhD, at St. Jude, and David Liu,
St. Jude Children’s Research Hospital provides the first gene therapy manufacturing and distribution cost report for hemophilia B. A St. Jude Children’s Research Hospital analysis found a major gap between the cost to manufacture and distribute hemophilia B gene therapy and the $2 million-plus price reportedly under consideration for hemophilia gene therapy now in development. The study appeared
A new report takes a close look at seven teen boys who developed myocarditis after COVID-19 vaccination, each of whom had similar symptoms, timing and outcomes. While health officials investigate whether vaccination caused this condition, Judith A. Guzman-Cottrill, D.O., a corresponding author of the report, said she hoped the report would raise clinicians’ awareness to suspect
Levels of antibodies in the blood of vaccinated people that are able to recognise and fight the new SARS-CoV-2 Delta variant first discovered in India (B.1.617.2) are on average lower than those against previously circulating variants in the UK, according to new laboratory data from the Francis Crick Institute and the National Institute for Health Research
A novel form of macrophage-based immunotherapy is effective at treating a broad spectrum of cancers, including those at advanced stages, according to a groundbreaking study led by Georgia State immunology professor Yuan Liu. Liu’s treatment works by leveraging macrophages, specialized white blood cells involved in the detection and elimination of cancer cells and other pathogens. Macrophages also activate
Peter MacCallum researchers are developing a potential new way to make CAR T-cell therapy more effective against breast cancer and other solid cancers. CAR T-cell therapy is a type of immunotherapy where a patient’s own immune cells are collected and reengineered, before being infused back into the patient to fight their cancer. But CAR T-cells
The approvals of the first gene and cell therapies in recent years have ushered in a new era of medicine. These cutting-edge approaches are poised to change the trajectory of how we treat cancer, fatal genetic conditions, and other devastating diseases. But these innovations also come with their own set of challenges, including issues of
All viruses, including SARS-CoV-2, the virus that causes COVID-19, change over time. Most changes have little to no impact on the virus’ properties. However, some changes may affect the virus’s properties, such as how easily it spreads, the associated disease severity, or the performance of vaccines, therapeutic medicines, diagnostic tools, or other public health and social measures. WHO, in collaboration with partners, expert networks, national authorities,
Deep Pharma Intelligence released a special 115-page analytical report Cell Therapies In Healthcare Landscape Overview 2021 (Stem Cells and CAR-Ts), which is the first comprehensive and systematic overview of cell therapies landscape by the company. This report is specifically focused on Stem Cell therapies and Chimeric Antigen Receptor T-cell (CAR-T) therapies, and it is the first
Scientific evidence that was used to inform the UK government’s key policies impacting millions of people during the first wave of COVID-19 including the rule of six and the first national stay-at-home order is published today [31 May] in the journal of the Royal Society. The Special Theme issue is compiled and guest edited by
AstraZeneca continues to discuss the cause of rare blood clots with regulators and scientists after German researchers said they discovered the link to its Covid-19 vaccines. The U.K. pharma company said the theory put forward by the Goethe University laboratory in Frankfurt on Wednesday is one of many that AstraZeneca scientists are investigating. “We are continuing to
Immunotherapies that fight cancer have been a life-saving advancement for many patients, but the approach only works on a few types of malignancies, leaving few treatment options for most cancer patients with solid tumors. Now, in two related papers published April 28, 2021, in Science Translational Medicine, researchers at UCSF have demonstrated how to engineer smart immune cells
Google also announced plans to release a new “AI-powered dermatology assist tool” that helps users understand what’s going on with their skin. Results have been published in Nature Medicine. Google has made a number of announcements at I/O 2021 to showcase the company’s technological advancements. It also announced plans to release a new “AI-powered dermatology assist
What is already known about this topic? Kindergarten through grade 5 schools educate and address the students’ physical, social, and emotional needs. Preventing SARS-CoV-2 transmission in schools is imperative for safe in-person learning. What is added by this report? COVID-19 incidence was 37% lower in schools that required teachers and staff members to use masks
Study shows treatment developed by international team restored immune function in more than 95% of patients in three clinical trials An experimental form of gene therapy developed by a team of researchers from UCLA and Great Ormond Street Hospital in London has successfully treated 48 of 50 children born with a rare and deadly inherited
Scientists from Hokkaido University have discovered a novel defensive response to SARS-CoV-2 that involves the viral pattern recognition receptor RIG-I. Upregulating expression of this protein could strengthen the immune response in COPD patients. In the 18 months since the first report of COVID-19 and the spread of the pandemic, there has been a large amount
Researchers at Massachusetts General Hospital (MGH) have identified the protein “signature” of severe COVID-19, which they describe in a new study published in Cell Reports Medicine. “We were interested in asking whether we could identify mechanisms that might be contributing to death in COVID-19,” says MGH infectious disease expert Marcia Goldberg, MD, who studies interactions between
There are many things we know and many things we don’t know about the B.1.617.2 variant. We know that it is spreading fast (roughly doubling each week in the UK and nearly tripling last week from 520 to 1313 cases), that it is becoming established in a number of areas across the country, and that
The most complete picture yet is coming into focus of how antibodies produced in people who effectively fight off SARS-CoV-2 work to neutralize the part of the virus responsible for causing infection. In the journal Science, researchers at The University of Texas at Austin describe the finding, which represents good news for designing the next generation of
Mucormycosis: hyphae of the fungus Mucor, from the paranasal sinus of a patient with diabetes mellitus. Public health officials report a rare black fungus infection, called mucormycosis, which is increasingly seen in vulnerable patients, including those with COVID-19 disease. India faces a global health crisis as the number of severe acute respiratory syndrome coronavirus 2
Vaccines are often described as one of the greatest public health interventions in recent history, based on the profound effect that they have had in decreasing global morbidity and mortality. Immunizations currently prevent 2-3 million deaths each year, and aside from sanitation and clean drinking water, they are credited as having the largest impact on population growth
In the early months of the COVID-19 pandemic, healthcare workers analyzing test results began noticing something strange: patients who had already recovered from COVID-19 would sometimes inexplicably test positive on a PCR test weeks or even months later. Although people can catch COVID-19 for a second time, this did not appear to be the case
Pfizer and BioNTech’s coronavirus reduces the risk of getting sick from COVID-19 by five- to 30-fold for fully immunized people, two new studies show. In one report, just 0.4 percent of healthcare workers in Israel who received both shots of the COVID-19 immunization later tested positive compared to 7.2 percent of unvaccinated employees. This means healthcare workers who
Moderna said its COVID-19 vaccine is 96 percent effective among youths aged 12 to 17, according to the results of its first clinical trials. Two-thirds of the 3,235 participants in trials in the United States received the vaccine and one-third were given a placebo. The study “showed vaccine efficacy against COVID-19 of 96%; mRNA-1273 was generally well
Norwegian and Danish researchers published a register study in BMJ of over 281,000 people who have received the AstraZeneca vaccine. – The study confirms previous findings from OUS and internationally. The registry study finds 11 additional cases of venous thrombosis among 100,000 vaccinated. The article that follows people who have received the AstraZeneca vaccine in
A new study is drawing the most detailed picture yet of SARS-CoV-2 infection in the lung, revealing mechanisms that result in lethal COVID-19, and may explain long-term complications and show how COVID-19 differs from other infectious diseases. Led by researchers at Columbia University Vagelos College of Physicians and Surgeons and Herbert Irving Comprehensive Cancer Center, the study found
In a major shot in the arm for the Pfizer-BioNTech COVID-19 vaccine, researchers have reported in two studies that it is highly effective in protecting against severe COVID-19 infections caused by the variants first reported in the UK and South Africa. In a study published in the New England Journal of Medicine on May 5, researchers analysed
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus is highly contagious and causes lymphocytopenia, but the underlying mechanisms are poorly understood. In this paper published on Nature fresearchers of Laboratory of Cell Engineering, Institute of Biotechnology, Beijing, China demonstrate that heterotypic cell-in-cell structures with lymphocytes inside multinucleate syncytia are prevalent in the lung tissues
A study published in July 2020 hypothesized a link between the presence of bradykinin, a well-known peptide, and severe cases of COVID-19. Vardan Karamyan, Ph.D., an associate professor and vice chair for the Texas Tech University Health Sciences Center (TTUHSC) Jerry H. Hodge School of Pharmacy Department of Pharmaceutical Sciences, had not previously conducted or
In the search for treatments for COVID-19, many researchers are focusing their attention on a specific protein that allows the virus to infect human cells. This protein, which cells carry on their surface, is called angiotensin converting enzyme 2 (ACE2) and provides the entry point for the coronavirus to enter cells. ACE2 is present in
COVID-19 is associated with a high incidence of thrombotic complications, which can be explained by the complex and unique interplay between coronaviruses and endothelial cells, the local and systemic inflammatory response, and the coagulation system. Empirically, an intensified dose of thrombosis prophylaxis is being used in patients admitted to hospital with COVID-19 and several guidelines
Clinical trials have shown the COVID-19 vaccines now being administered around the country are highly effective in protecting fully vaccinated individuals from the coronavirus SARS-CoV-2. But will they continue to offer sufficient protection as the frequency of more transmissible and, in some cases, deadly emerging variants rise? More study and time is needed to fully
Spinal fusion is frequently performed to restore spinal stability in patients with spinal diseases, such as spinal stenosis, vertebral fractures, progressive deformities, and instability. In the past two decades, there has been marked increase in the number of people over 65 years in age who have needed spinal fusion surgery. While autogenous bone grafts have
Cerebral venous sinus thrombosis (CVST) with thrombocytopenia, a rare and serious condition, has been described in Europe following receipt of the ChAdOx1 nCoV-19 vaccine (Oxford/AstraZeneca), which uses a chimpanzee adenoviral vector. A mechanism similar to autoimmune heparin-induced thrombocytopenia (HIT) has been proposed. In the US, the Ad26.COV2.S COVID-19 vaccine (Janssen/Johnson & Johnson), which uses a
In recent years, the interest in adipose tissue mesenchymal cell–derived extracellular vesicles (AT-MSC-EVs) has increasingly grown. Numerous articles support the potential of human AT-MSC-EVs as a new therapeutic option for treatment of diverse diseases in the musculoskeletal and cardiovascular systems, kidney, skin, and immune system, among others. This approach makes use of the molecules transported
Researchers have found that a natural molecule can effectively block the binding of a subset of human antibodies to SARS-CoV-2. The discovery may help explain why some COVID-19 patients can become severely ill despite having high levels of antibodies against the virus. In their research, published in Science Advances today (22 April 2021), teams from the Francis
The National Institutes of Health has made significant updates to its guidelines on treating people with COVID-19. What’s New in the Guidelines Last Updated: April 21, 2021 The Coronavirus Disease 2019 (COVID-19) Treatment Guidelines is published in an electronic format that can be updated in step with the rapid pace and growing volume of information regarding the
Chimeric antigen receptor (CAR) T-cell therapy can induce side-effects such as cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome (ICANS), which often require intensive care unit admission. The aim of the study, published in The Lancet Haematology was to describe management of critically ill CAR T-cell recipients in intensive care. An international, multicentre, observational
Research has shown that people with red hair perceive pain differently than others. They may be more sensitive to certain types of pain and can require higher doses of some pain-killing medications. However, studies suggest that their general pain tolerance may be higher. People with red hair also respond more effectively to opioid pain medications,
COVID-19, caused by SARS-CoV-2 virus infection, has changed human behavior patterns since it became a global pandemic. To date, more than 136 million people have suffered from the disease and, of these, more than 2.9 million have lost their lives. The symptoms of the infection vary widely, from individuals who show no clinical symptoms to those who
Cases of unusual thrombosis and thrombocytopenia after administration of the ChAdOx1 nCoV‐19 vaccine (AstraZeneca) have been reported. The term vaccine‐induced prothrombotic immune thrombocytopenia (VIPIT) was coined to reflect this new phenomenon. In vitro experiments with VIPIT patient sera indicated that high dose intravenous immunoglobulins (IVIG) competitively inhibit the platelet activating properties of ChAdOx1 nCoV‐19 vaccine induced
In a paper recently published on Cell, an emerging SARS-CoV-2 variant was identified by viral whole-genome sequencing of 2,172 nasal/nasopharyngeal swab samples from 44 counties in California, a state in the Western United States. Named B.1.427/B.1.429 to denote its 2 lineages, the variant emerged in May 2020 and increased from 0% to >50% of sequenced
At its meeting of 20 April 2021, EMA’s safety committee (PRAC) concluded that a warning about unusual blood clots with low blood platelets should be added to the product information for COVID-19 Vaccine Janssen. PRAC also concluded that these events should be listed as very rare side effects of the vaccine. In reaching its conclusion, the Committee took into
For weeks, Americans looked on as other countries grappled with case reports of rare, sometimes fatal blood abnormalities among those who had received the AstraZeneca vaccine against COVID-19. That vaccine has not yet been authorized by the FDA, so restrictions on its use throughout Europe did not get that much attention in the United States.
Precision medicine is, broadly speaking, a sweeping aspiration that will be achieved, or not, depending on the convergence of many different disciplines. The most important of these disciplines are molecular genetics and cell biology. Besides contributing to precision medicine directly, they also contribute through 3D bioprinting. In 3D bioprinting, molecular genetics and cell biology are
The mainstay of control of the coronavirus disease 2019 (Covid-19) pandemic is vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Within a year, several vaccines have been developed and millions of doses delivered. Reporting of adverse events is a critical postmarketing activity. In this paper are reported findings in 23 patients who presented with
Despite progress in clinical care for patients with coronavirus disease 2019 (COVID-19), population-wide interventions are still crucial to manage the pandemic, which has been aggravated by the emergence of new, highly transmissible variants. In this study, we combined the SIDARTHE model, which predicts the spread of SARS-CoV-2 infections, with a newdata-based model that projects new
Researchers at the University of Oxford have today reported that the risk of the rare blood clotting known as cerebral venous thrombosis (CVT) following COVID-19 infection is around 100 times greater than normal, several times higher than it is post-vaccination or following influenza. The study authors, led by Professor Paul Harrison and Dr Maxime Taquet
PTC Therapeutics has reported results from Part 2 of the pivotal FIREFISH trial of Evrysdi (risdiplam), which demonstrated that infants with type 1 spinal muscular atrophy (SMA) continued to show improvements in survival and key motor milestones after two years of treatment. PTC Therapeutics has reported results from Part 2 of the pivotal FIREFISH trial
The use of this vaccine in several countries in South America and eastern Europe, besides Russia, mandates that its efficacy against the new resistant variants be tested, as they are being found more commonly in these regions.Generation of replication-competent VSV bearing SARS-CoV-2 spike (rcVSV-CoV2-S). (A) Schematic of the rcVSV-CoV2-S genomic coding construct and the virus
A team led by investigators at Weill Cornell Medicine and NewYork-Presbyterian has used advanced technology and analytics to map, at single-cell resolution, the cellular landscape of diseased lung tissue in severe COVID-19 and other infectious lung diseases. In the study, published online March 29 in Nature, the researchers imaged autopsied lung tissue in a way that
Cerebral venous sinus thrombosis (CVST) occurs when a blood clot forms in the brain’s venous sinuses. This prevents blood from draining out of the brain. As a result, blood cells may break and leak blood into the brain tissues, forming a hemorrhage. This chain of events is part of a stroke that can occur in adults
Increased understanding of whether individuals who have recovered from COVID-19 are protected from future SARS-CoV-2 infection is an urgent requirement. In a paper published on The Lancet it was investigated whether antibodies against SARS-CoV-2 were associated with a decreased risk of symptomatic and asymptomatic reinfection. A large, multicentre, prospective cohort study was done, with participants
We wish to raise our concern with the MHRA regarding wording included in recent changes in MHRA guidance on the use of the AstraZeneca COVID-19 vaccine. The MHRA Guidance issued 7th April 2021 (https://www.gov.uk/government/news/mhra-issues-new-advice-concluding-a-possible-link-between-covid-19-vaccine-astrazeneca-and-extremely-rare-unlikely-to-occur-blood-clots ) Indicates: The MHRA is not recommending age restrictions in COVID-19 Vaccine AstraZeneca use. As a precaution, administration of COVID-19 Vaccine AstraZeneca
EMA, ISTH, WHO and many countries recommend benefit of COVID-19 vaccination outweighs the risks. Risks of adverse events no higher in people with bleeding disorders The European Medicines Agency (EMA) Pharmacovigilance Risk Assessment Committee (PRAC), following investigation of isolated cases of unusual blood clotting with low blood platelets that have occurred in a small number
All medical treatments have potential harms as well as potential benefits, and it’s important to be able to weigh these against each other. With vaccines, the benefits are particularly complex as they can involve benefits to others as well as to ourselves – and the harms can feel particularly acute because we take vaccines when
Doctors might have figured out why AstraZeneca Vaccine Induced Immune Thrombotic Thrombocytopenia (VITT) may cause life-threatening blood clots in a group of 16 patients with very rare cases of thrombosis and thrombocytopenia. The discovery, made in a pair of reports published online Friday in the New England Journal of Medicine, could be key to the global
The Stem Cells for Huntington’s Disease ( SC4HD ) is a new international consortium created to drive advanced therapy drugs (ATMP), through stem cell transplantation, to treat Huntington’s disease. The entity, made up of twenty-eight renowned researchers from ten countries, has been officially featured in the Journal of Huntington’s Disease . The main objectives of the SC4HD consortium are to
AstraZeneca’s COVID-19 vaccine has dominated headlines as reports of rare blood clots mounted, but, now, European drug safety regulators are investigating potential clotting risks from Johnson & Johnson’s vaccine. So far in the J&J vaccine’s U.S. rollout, EU officials have tracked three cases of unusual blood clots with low blood platelets following vaccination, the European
Data from a UK phase 2/3 clinical trial suggest the AstraZeneca-Oxford COVID-vaccine is 70.4% effective against symptomatic COVID-19 caused by the B117 variant, which was identified in the United Kingdom in late 2020. The data, published in The Lancet yesterday, also showed it was 28.9% effective at preventing asymptomatic infections or cases with unknown symptoms. Overall efficacy was
Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a potentially fatal thrombotic microangiopathy caused by autoantibody-mediated severe deficiency of ADAMTS13. Standardized definitions of response, exacerbation, remission, and relapse were initially proposed in 2003 and modified by the International Working Group for TTP in 2017. These definitions, which have been widely used in clinical practice and research, are
A common antiparasitic drug could block lung damage in people with coronavirus, new research published in Nature has found. Using robotic technology to screen over 3,000 approved drugs known to be safe in humans, researchers found Niclosamide – a drug used to treat tapeworm infections – was effective at stopping the viral replication and fusion
EMA confirms overall benefit-risk remains positive EMA’s safety committee (PRAC) has concluded today that unusual blood clots with low blood platelets should be listed as very rare side effects of Vaxzevria (formerly COVID-19 Vaccine AstraZeneca). In reaching its conclusion, the committee took into consideration all currently available evidence, including the advice from an ad hoc
An expert team of British Society for Haematology have recently been involved in diagnosing and managing a rare syndrome of thrombosis associated with low platelets which have been reported in a few cases. At the moment, any causal association with coronavirus vaccination has not been established. However, are identified patients with this syndrome in proximity
SARS-CoV-2 showed the world with devastating clarity the threat undetected viruses can pose to global public health. SpillOver, a new web application developed by scientists at the University of California, Davis, and contributed to by experts from all over the world, ranks the risk of wildlife-to-human spillover for newly discovered viruses. SpillOver is the first open-source risk
NIH research suggests protective effects of vaccination remain intact When variants of SARS-CoV-2 (the virus that causes COVID-19) emerged in late 2020, concern arose that they might elude protective immune responses generated by prior infection or vaccination, potentially making re-infection more likely or vaccination less effective. To investigate this possibility, researchers from the National Institute
Approval of ide-cel for adults who have relapsed after four or more prior lines of therapy follows clinical trials led by Dana-Farber Cancer Institute investigators The Food and Drug Administration (FDA) has granted its first approval of a CAR T-cell therapy for adults with multiple myeloma, bringing welcome hope for patients eligible for the treatment, according to researchers
Long COVID can affect multiple organ systems and the most common symptoms include fatigue, shortness of breath, brain fog, anxiety, depression, and post-traumatic stress disorder (PTSD) Based on the limited data available, at least one-third of patients hospitalized for COVID-19 studied to date have experienced such long-term effects Physicians across the country have analyzed the
Mount Sinai researchers have found that a widely available and inexpensive drug targeting inflammatory genes has reduced morbidity and mortality in mice infected with SARS-CoV-2, the virus that causes COVID-19. In a study published today in the journal Cell, the team reported that the drug, Topotecan (TPT), inhibited the expression of inflammatory genes in the lungs
Drug already in human trials as cancer therapy appears to disrupt coronavirus replication A collaboration among scientists from UCLA and other universities in California, Delaware and Germany, as well as a German pharmaceutical company, has singled out a compound that shows promise for treating SARS-CoV-2, the virus that causes COVID-19. In a series of experiments
As devastating as this pandemic has been, it’s truly inspiring to see the many innovative ways in which researchers around the world have enlisted the help of everyday citizens to beat COVID-19. An intriguing example is the COVID Symptom Study’s smartphone-based app, which already has been downloaded millions of times, mostly in the United States
NIH-funded findings point to a role for saliva in SARS-CoV-2 transmission. An international team of scientists has found evidence that SARS-CoV-2, the virus that causes COVID-19, infects cells in the mouth. While it’s well known that the upper airways and lungs are primary sites of SARS-CoV-2 infection, there are clues the virus can infect cells
Study shows that antibody longevity varies widely from 40 days to as long as several decades and not everyone who has recovered from COVID-19 is immune from reinfection Individuals with low levels of neutralising antibodies may still be protected if they have robust T-cell immunity Blood tests and a computer algorithm suggest annual vaccinations might
Key Takeaways A single injection of a gene therapy involving what are called zinc fingers dramatically reduced levels of tau, a protein implicated in Alzheimer’s disease, in mice with the condition. The treatment was long lasting, caused no side effects, and reduced Alzheimer’s-related damage in the brain. The technology worked just the way we had
Gene therapy can be used to restore cell function in monogenic disorders or to endow cells with new capabilities, such as improved killing of cancer cells, expression of suicide genes for controlled elimination of cell populations, or protection against chemotherapy or viral infection. While gene therapies were originally most often used to treat monogenic diseases
Chimeric antigen receptor (CAR)-T cell therapies are on the verge of becoming powerful immunotherapeutic tools forcombating hematological diseases confronted with pressing medical needs. Lately, CAR-NK cell therapies have also come into focus as novel therapeutic options to address hurdles related to CAR-T cell therapies, such as therapy-induced side effects. Currently, more than 500 CAR-T and
Late Monday, the Data and Safety Monitoring Board (DSMB) notified NIAID, BARDA, and AstraZeneca that it was concerned by information released by AstraZeneca on initial data from its COVID-19 vaccine clinical trial. The DSMB expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the
Researchers from the George Washington University found that aspirin may have lung-protective effects and reduce the need for mechanical ventilation, ICU admission and in-hospital mortality in hospitalized COVID-19 patients. George Washington University researchers found low dose aspirin may reduce the need for mechanical ventilation, ICU admission and in-hospital mortality in hospitalized COVID-19 patients. Final results
79% vaccine efficacy at preventing symptomatic COVID-19 100% efficacy against severe or critical disease and hospitalisation Comparable efficacy result across ethnicity and age,with 80% efficacy in participants aged 65 years and over Favourable reactogenicity and overall safety profile The AstraZeneca US Phase III trial of AZD1222 demonstrated statistically significant vaccine efficacy of 79% at preventing
13 cases of a venous cerebral sinus or cerebral vein thrombosis following >1,6 million doses were reported in Germany. The thrombosis occurred 4-16 days after the vaccination with the AstraZeneca COVID-19 vaccine in twelve women and one man aged 20–63 years. The patients had one at the same time thrombosis and thrombocytopenia due to autoantibodies.
EMA has just published the new product information leaflet for Astrazeneca Covid-19 vaccine after investigations of thrombosis rare cases reported. In the section 4.4 Special warnings and precautions for use has been added the following: Thrombocytopenia and coagulation disordersA combination of thrombosis and thrombocytopenia, in some cases accompanied by bleeding, hasbeen observed very rarely following
A study recently published in the journal Science looked into how CAR T immunotherapy could be used to treat solid tumours in addition to leukaemias. The programming of CAR T cells opens avenues for applying cell therapies to, for example, breast cancer or ovarian cancer in the future. In cancer immunotherapy, cells in the patient’s
From the early days of the COVID-19 pandemic, a distinct coagulation disturbance of SARS-CoV-2 infection has been recognized. This thrombo-inflammatory phenotype, characterized by endotheliopathy, hypercoagulability, and coagulation activation, results in an increased risk of thromboembolic events. Initial observational cohort studies described high rates of venous thromboembolism (VTE) in critically ill patients with COVID-19, despite consistent use
In The Lancet, Zhenyu He and colleagues report their cross-sectional study of serological responses of morethan 9500 individuals from 3600 households in Wuhan, the early epicentre for the COVID-19 outbreak. The study was initiated shortly after lockdown in Wuhan ceased in April, 2020, with follow-up over two timepoints (June and October–December, 2020). In this cross-sectional,
CDC’s national genomic surveillance program identifies new and emerging SARS-CoV-2 variants to determine implications for COVID-19 diagnostics, treatments, or vaccines authorized for use in the United States. Monitoring the spread of emerging variants in the United States relies on widespread, rapid sequencing. To accelerate sequencing in the United States, CDC has contracted with commercial diagnostic laboratories, and,
EMA’s safety committee, PRAC, concluded its preliminary review of a signal of blood clots in people vaccinated with COVID-19 Vaccine AstraZeneca at its extraordinary meeting of 18 March 2021. The Committee confirmed that: the benefits of the vaccine in combating the still widespread threat of COVID-19 (which itself results in clotting problems and may be fatal)
Thrombosis affecting the pulmonary and systemic vasculature is common during severe COVID-19 and causes adverse outcomes. Although thrombosis likely results from inflammatory activation of vascular cells, the mediators of thrombosis remain unconfirmed. In a cross-sectional cohort of 36 severe COVID-19 patients, it was shown that markedly increased plasma von Willebrand factor (VWF) levels were accompanied
The main hypothesis of this retrospective study is that VWF biomarkers are associated with coagulation in COVID-19. It was performed a balanced retrospective study of COVID-19 hospitalized patients with similar demographics and comorbidities and a wide range of D-dimer levels to study how VWF biomarkers correlate with coagulation, intravascular hemolysis, and outcome. Indeed, we show
Researchers from Cleveland Clinic’s Florida Research and Innovation Center (FRIC) have identified a potential new target for anti-COVID-19 therapies. Their findings were published in Nature Microbiology. Led by FRIC scientific director Michaela Gack, Ph.D., the team discovered that a coronavirus enzyme called PLpro (papain-like protease) blocks the body’s immune response to the infection. More research is necessary, but the
The SARS-CoV-2 spike gene has accumulated mutations within the receptor-binding domain (RBD) and the N-terminal domain (NTD). These domains are major targets of the antibody response elicited by the vaccines. The RBD mutations include the N501Y mutation, which is associated with increased affinity of SARS-CoV-2 to the angiotensin-converting enzyme 2 (ACE2) receptor. In contrast, the E484K
A number of European nations, including Germany, France, Italy and Sweden, have suspended use of the Oxford/AstraZeneca covid‑19 vaccine over blood clot concerns. The World Health Organization and the European Medicines Agency (EMA) have both emphasised that there is currently no evidence linking the vaccine to blood clots and recommend that countries continue using it. Emer Cooke, director of
Restrictions put in place to contain COVID-19 may be particularly difficult for teens, who rely heavily on their peer and social connections for emotional support. In 2021, the C.S. Mott Children’s Hospital National Poll on Children’s Health asked a national sample of parents about the emotional impact pandemic restrictions have had on their teens age
52,4% patients have symptoms of major depressive disorder after COVID-19, as published in a study of Massachusetts General Hospital More than half of individuals with prior COVID-19 illness have met the criteria for symptoms of major depressive disorder, according to a research letter published online March 12 in JAMA Network Open. Roy H. Perlis, M.D., from
The coronavirus disease-19 (COVID-19) pandemic has cost lives and economic hardships globally. Various studies have found a number of different factors, such as hyperinflammation and exhausted/suppressed T cell responses to the etiological SARS coronavirus-2 (SARS-CoV-2), being associated with severe COVID-19. However, sieving the causative from associative factors of respiratory dysfunction has remained rudimentary. In this
Key Takeaways Neutralizing antibodies induced by the Pfizer and Moderna COVID-19 vaccines were significantly less effective against the variants first described in Brazil/Japan and South Africa. While the ability of these variants to resist neutralizing antibodies is concerning, it doesn’t mean the vaccines won’t be effective. Understanding which mutations are most likely to allow the
The risk for invasive mechanical ventilation, hospitalization and death in those with COVID-19 increased with BMI, according to research published in MMWR. “The findings in this report highlight a dose-response relationship between higher BMI and severe COVID-19–associated illness and underscore the need for progressively intensive illness management as obesity severity increases,” LyudmylaKompaniyets, PhD, a postdoctoral research fellow at the CDC,
There are no therapeutics available that have been developed for COVID-19 treatment. Repurposing of already available medication for COVID-19 therapy is an attractive option to shorten the road to treatment development. The drug Camostat could be suitable. Camostat exerts antiviral activity by blocking the protease TMPRSS2, which is used by SARS-CoV-2 for entry into cells.
Dr. Samuel Goldhaber, President of North American Thrombosis Forum (NATF) and Associate Chief and Clinical Director of the Division of Cardiovascular Medicine at Brigham and Women’s Hospital, answers the most pressing questions from patients about the COVID-19 vaccine and blood clots.
In an article published in The Lancet, RCP president Professor Andrew Goddard and RCP Global vice president Dr Mumtaz Patel call for system-wide support to protect clinicians from harm. The COVID-19 pandemic has placed huge demands on global health systems which are testing doctors and health-care workers to the limits of their professional competence and taking
On Feb 22, 2021, the UK Government announced that schools in England would fully reopen on March 8, 2021. While returning to school as soon as possible is imperative for the education, social development, and mental and physical welfare of children, not enough has been done to make schools safer for students and staff. Primary
A highly infectious variant of COVID-19 that has spread around the world since it was first discovered in Britain late last year is between 30% and 100% more deadly than previous dominant variants, researchers said on Wednesday. In a study that compared death rates among people in Britain infected with the new SARS-CoV-2 variant known
Sara Ghorashian, PhD, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK, outlines the challenges associated with CAR T-cell therapy for pediatric B-cell acute lymphoblastic leukemia (ALL). Discovering the best treatment phasing with other immunotherapies, such as blinatumomab and inotuzumab, improving the toxicity profile, and CAR T-cell persistence are some of the remaining
Most are transient, but some develop into life-threatening disorders Neurologic symptoms occurred frequently in children and adolescents hospitalized with COVID-19, a large case series of pediatric patients in the U.S. showed. Of 1,695 people 21 or younger hospitalized for acute COVID-19 or multisystem inflammatory syndrome in children (MIS-C), more than one in five (22%) had
A group of US and European epidemiologists on Tuesday launched an open international database that presents granular information on 5 million anonymized COVID-19 cases from more than 100 countries. Each case record in the database, which is housed at Global.health, contains up to 40 variables, including information such as the patient’s demographics and location, the date
Vaccines to prevent COVID-19 infection are crucial for an effective global pandemic response. In The Lancet, Merryn Voysey and colleagues report the updated primary efficacy results for the Oxford–AstraZeneca ChAdOx1 nCoV-19 (AZD1222) vaccine from three single-blind, randomised controlled trials in the UK and Brazil and one double-blind study in South Africa. A subsequent report of
A variant of SARS-CoV-2 that emerged in southeast England in November 2020 is more transmissible than pre-existing variants, a new modeling study of Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, published on Science, finds. Further analyses suggest the variant B.1.1.7 will lead to large resurgences of COVID-19 cases.
All current vaccines for COVID-19 utilize ancestral wild type SARS-CoV-2 Spike with the goal of generating protective neutralizing antibodies. The recent emergence and rapid spread of several SARS-CoV-2 variants carrying multiple Spike mutations raise concerns about possible immune escape. One variant, first identified in the United Kingdom (B.1.1.7, also called 501Y.V1 or 20I), contains eight
“The Janssen COVID-19 vaccine is a very welcome addition to the arsenal of COVID-19 vaccines and other prevention strategies. When tested among 45,000 volunteers, the single-injection vaccine proved 77 percent effective in preventing severe/critical COVID-19 occurring at least 14 days after vaccination and 85 percent effective in preventing severe/critical COVID-19 occurring at least 28 days
Laboratory experiments have shown mouthwash can quickly kill coronaviruses, but there’s no evidence mouthwash can prevent the virus from infecting people. The Adams School of Dentistry is investigating how well mouthwash works to reduce the amount of SARS-CoV-2. Researchers at the University of North Carolina at Chapel Hill Adams School of Dentistry have launched a clinical trial to test
The Pfizer BioNTech coronavirus vaccine produces as good results in the “real world” as have been previously documented in randomised trials. A case control study, which has been peer reviewed and published in the New England Journal of Medicine, compared 596 618 people who were newly vaccinated in Israel and matched them to unvaccinated controls. Two doses
Infection by the new corona virus strain SARS-CoV-2 and its related syndrome COVID-19 has been associated with more than two million deaths worldwide. Patients of higher age and with preexisting chronic health conditions are at an increased risk of fatal disease outcome. However, detailed information on causes of death and the contribution of pre-existing health
People who have had evidence of a prior infection with SARS-CoV-2, the virus that causes COVID-19, appear to be well protected against being reinfected with the virus, at least for a few months, according to a newly published study from the National Cancer Institute (NCI). This finding may explain why reinfection appears to be relatively rare,
The Food and Drug Administration’s staff released a briefing document on Wednesday endorsing Johnson & Johnson’s one-shot coronavirus vaccine as safe and effective. An FDA advisory panel will meet Friday to review the briefing document and vote on whether to recommend an emergency use authorization (EUA). The FDA could then issue the (EUA) as soon as this
The 501Y.V2 variants of SARS-CoV-2 containing multiple mutations in Spike are now dominant in South Africa and are rapidly spreading to other countries. In this paper, experiments with 18 pseudotyped viruses showed that the 501Y.V2 variants do not confer increased infectivity in multiple cell types except for murine ACE2-overexpressing cells, where a substantial increase in
The race to produce vaccines against SARS-CoV-2 began when the first sequence was published, and this forms the basis for vaccines currently deployed globally. Independent lineages of SARS-CoV-2 have recently been reported: UK–B.1.1.7, South Africa–B.1.351 and Brazil–P.1. These variants have multiple changes in the immunodominant spike protein which facilitates viral cell entry via the Angiotensin
Despite dramatic improvements in survival, multiple myeloma (MM) remains largely incurable, and most patients develop disease that is refractory to available treatment options. A paper just published on Blood Advances by researchers of Department of Hematological Malignancies and Cellular Therapeutics, Kansas University Medical Center, Westwood, Division of Gastroenterology, University of Toledo, Division of Hematology and
Human monoclonal antibodies are safe, preventive and therapeutic tools, that can be rapidly developed to help restore the massive health and economic disruption caused by the coronavirus disease 2019 (COVID-19) pandemic. In this just published paper on Cell researchers of Fondazione Toscana Life Sciences, National Institute for Infectious Diseases Lazzaro Spallanzani, Imperial College London and
Hematopoietic cell transplantation (HCT) is an established procedure for many acquired or inherited disorders of the hematopoietic system, benign or neoplastic, including those of the immune system, and as enzyme replacement in metabolic disorders. The activity survey of the EBMT, describing the status of HCT, has become an instrument with which to observe trends and
Children are protected from severe COVID-19 because their innate immune system is quick to attack the virus, a new study has found. The research led by the Murdoch Children’s Research Institute (MCRI) and published in Nature Communications, found that specialised cells in a child’s immune system rapidly target the new coronavirus (SARS-CoV-2). MCRI’s Dr Melanie Neeland said the
The cases of rash on mRNA vaccines are almost non-existent and no deaths have occurred. A research published in the medical journal JAMA, points out that the probability of developing anaphylaxis is only 0.000377%, as out of the approximately 17.5 million vaccinations, no deaths occurred, while only 66 people developed anaphylaxis to mRNA vaccines. A
Enrollment has begun to test additional investigational drugs in the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) program. ACTIV is a public-private partnership program to create a coordinated research strategy that prioritizes and speeds development of promising COVID-19 treatments and vaccines. The new agents entering the randomized, placebo-controlled study are part of ACTIV-2, an adaptive trial designed to
CAL.20C Variant, Now Found in Nearly Half of Southern California Cases, Is Detected in 19 US States, Washington, D.C., and Six Foreign Countries, Cedars-Sinai Reports A new strain of the coronavirus in Southern California, first reported last month by Cedars-Sinai, is rapidly spreading across the country and around the world as travelers apparently carry the
Editorial emphasizes need for global response. The rise of several significant variants of SARS-CoV-2, the virus that causes COVID-19, has attracted the attention of health and science experts worldwide. In an editorial published today in JAMA: The Journal of the American Medical Association, experts from the National Institute of Allergy and Infectious Diseases (NIAID), part of the
In drug development, scientific progression was never a solo effort. Rather, to advance new therapies, particularly cell and gene therapies, drug development is a team sport. Why is the team so important? Oftentimes when one tests novel cell and gene therapies in the clinic for the first time, one is treading completely new ground. The
Characterization of the humoral response to SARS-CoV-2, the etiological agent of COVID-19, is essential to help control the infection. The neutralization activity of plasma from COVID-19 patients decreases rapidly during the first weeks after recovery. However, the specific role of each immunoglobulin isotype in the overall neutralizing capacity is still not well understood. In this
Countering COVID-19 mutations and designing updated vaccines could occur at lightning speeds thanks to a new, USC-developed AI framework. USC researchers have developed a new method to counter emergent mutations of the coronavirus and hasten vaccine development to stop the pathogen responsible for killing thousands of people and ruining the economy. Using artificial intelligence (AI),
The Pfizer / BioNTech vaccine is effective against covid-19 variants originating in the UK and South Africa. This is the result of a study published this Monday in Nature Medicine , which showed better results in the first case, the British variant (called B.1.1.7), than in the second, the South African, or B.1.351. The differences, however, are small.
A clinical study led by Dr. Jordan Feld, a liver specialist at UHN’s Toronto Centre for Liver Disease, showed an experimental antiviral drug can significantly speed up recovery for COVID-19 outpatients – patients who do not need to be hospitalized. This could become an important intervention to treat infected patients and help curb community spread,
Breyanzi demonstrated a 73% overall response rate and 54% complete response (CR) rate in the largest pivotal trial in 3L+ LBCL, TRANSCEND NHL 001 trial Breyanzi demonstrated sustained responses in patients who achieved a CR with median duration of response not reached Grade ≥3 cytokine release syndrome and Grade ≥3 neurologic toxicities following Breyanzi treatment occurred in 4% and
SARS-CoV-2 mutations similar to those in the B1.1.7 UK variant could arise in cases of chronic infection, where treatment over an extended period can provide the virus multiple opportunities to evolve, say scientists. Writing in Nature, a team led by Cambridge researchers report how they were able to observe SARS-CoV-2 mutating in the case of an
What do we know about the E484K mutation? The E484K mutation is not a new variant in itself, it’s a mutation which occurs in different variants and has already been found in the South African (B.1.351) and Brazilian (B.1.1.28) variants. The mutation is in the spike protein and appears to have an impact on the
COVID-19 is a current global health threat caused by the novel coronavirus SARS-CoV-2. Emerging evidence indicates that SARS-CoV-2 elicits a dysregulated immune response and a delayed interferons (IFNs) expression in patients, which contribute largely to the viral pathogenesis and development of COVID-19. However, underlying mechanisms remain to be elucidated. In this paper, it’s reported the
The Johannesburg Witwatersrand University Vaccines and Infectious Diseases Analytics (VIDA) Research Unit, which runs the Oxford Covid-19 vaccine trial in South Africa, has announced results. In an analysis, submitted as a pre-print prior to peer-review publication, a two-dose regimen of the ChAdOx1 nCoV-19 vaccine provides minimal protection against mild-moderate COVID-19 infection from the B.1.351 coronavirus
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) will perform an accelerated assessment of the Marketing Authorisation Application (MAA) for the B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR-T) therapy ciltacabtagene autoleucel (cilta-cel). Accelerated assessment is
A more contagious variant of the coronavirus first found in Britain is spreading rapidly in the United States, doubling roughly every 10 days, according to a new study. Analyzing half a million coronavirus tests and hundreds of genomes, a team of researchers predicted that in a month this variant could become predominant in the United States,
We need open data, especially open SARS-CoV-2 sequence data, and open science to beat COVID-19 and to prepare for future outbreaks. Why open data is so important When responding to a health crisis, data play a critical role in understanding transmission, infection and symptoms, and in identifying drug targets, developing vaccines and designing public health
Since B.1.1.7 was first identified in September in southern England, it has become the dominant variant in the United Kingdom and has spread to more than 30 countries. To investigate whether the lineage causes an increased risk of dying, Nicholas Davies, an epidemiologist at the LSHTM, and colleagues analysed data from more than 850,000 people
There are several approved treatments for coronavirus disease 2019 (COVID-19) in hospitalized patients but few for patients who are not sick enough to be hospitalized. Monoclonal antibodies are a new treatment for outpatients with COVID-19 who are at risk of progression to severe disease. What Is a Monoclonal Antibody? An antibody is a protein that is naturally
The US Food and Drug Administration (FDA) revised its emergency use authorization (EUA) for COVID-19 convalescent plasma to limit its use to high titer units and only in hospitalized patients who are in the early stages of the disease or who have impaired humoral immunity. Convalescent plasma emerged as a potential treatment for COVID-19 in the
Using patient data, artificial intelligence can make a 90 percent accurate assessment of whether a person will die from COVID-19 or not, according to new research at the University of Copenhagen. Body mass index (BMI), gender and high blood pressure are among the most heavily weighted factors. The research can be used to predict the
In a recent paper, the research team around Prof. Antonio del Sol from the University’s Luxembourg Centre for Systems Biomedicine (LCSB) describes a new method of how molecules can be identified that amplify and maintain the inflammatory response upon an infection. They use their novel method to identify these molecules in COVID-19 patients and suggest new
How do vaccines work? Germs are all around us, both in our environment and in our bodies. When a person is susceptible and they encounter a harmful organism, it can lead to disease and death. The body has many ways of defending itself against pathogens (disease-causing organisms). Skin, mucus, and cilia (microscopic hairs that move debris away
The COVID-19 pandemic continues to constitute a huge threat to public health worldwide and despite the efforts and advances to untangle the mechanisms of SARS-CoV-2 infection and transmission among humans, we are still blind to the overall COVID-19 pathology and its consequences. The results presented in this paper might help understand the emergent erythropoiesis and
A new study by Yale researchers found a significant association between the availability of hospital resources — particularly ICU beds — and patient mortality during the early weeks of the COVID-19 pandemic. This was especially true at hospitals in the northeastern U.S. which were hardest hit by the first surge of patient cases, according to
What is RNA? How do mRNA vaccines work, and how effective are they? What does this mean for the COVID-19 pandemic? In a short video, Yale experts Saad Omer, Onyema Ogbuagu, and Akiko Iwasaki explain the science.
Chimeric antigen receptor T-cell therapy, or CAR T, has been a breakthrough in the treatment of blood cancers such as acute lymphoblastic leukemia and diffuse large B-cell lymphoma. Clinical studies have shown overall response rates of more than 80% with an ongoing response of nearly 40% more than two years after therapy. However, the cellular
A Russian vaccine against COVID-19 — Gam-COVID-Vac (dubbed “Sputnik V”) — shows 92% efficacy in interim results from a phase 3 trial reported in The Lancet. The two-dose vaccine uses replication-deficient adenoviruses to deliver a SARS-CoV-2 glycoprotein as the antigenic stimulus. Doses are administered at 21-day intervals, and the vaccine may be stored in normal freezers.
The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, MHRA, with a regimen of two standard doses given with an interval of between 4 and 12 weeks. The planned rollout in the UK will involve vaccinating people in high risk categories with their first dose immediately, and delivering
In one of the most puzzling and worrisome developments in the pandemic, scientists are racing to explain what’s happening in Manaus, Brazil, a city of 2.2 million at the edge of the country’s rainforest that is experiencing a second explosive outbreak, even though the first one was so bad it was thought to have produced
People infected with the new variant of covid-19 discovered in the South East of England (known as B.1.1.7 or VUI 202012/01) are more likely to have a cough, sore throat, fatigue, or myalgia than those infected with other variants, the Office for National Statistics has reported. The data, published 27 January, also show that people
Researchers at the University of Arizona are developing a COVID-19 testing method that uses a smartphone microscope to analyze saliva samples and deliver results in about 10 minutes. The UArizona research team, led by biomedical engineering professor Jeong-Yeol Yoon, aims to combine the speed of existing nasal swab antigen tests with the high accuracy of nasal swab PCR,
In the 14 studies with longitudinal data that reported information on the evolution of symptomatic status, nearly three quarters of persons who tested positive but had no symptoms at the time of testing remainedasymptomatic. Current data suggest that infected persons without symptoms—including both presymptomatic and asymptomatic persons—account for more than 40% of all SARS-CoV-2 transmission.
1. Treatment with IV ferric carboxymaltose reduced the risk of heart failure hospitalizations in patients with iron deficiency and acute heart failure with a left ventricular ejection fraction less than 50%. 2. IV ferric carboxymaltose was generally safe but had no significant effect on the risk of cardiovascular death compared to placebo. Evidence Rating Level: 1
U.S. schools operating in-person have experienced low transmission of the Chinese coronavirus, particularly when mitigation strategies such as masking and social distancing are in place, U.S. Centers for Disease Control and Prevention (CDC) Director Rochelle Walensky stressed on Friday, citing new findings by the health agency. Under President Joe Biden, the CDC has expressed support
The key question in 2021 is whether the new strains of coronavirus will be able to eradicate the vaccine-induced immunity. This paper on JAMA by John P Moore and Paul A Offit of Cornell and Pennsylvania Universities has been recently published on JAMA. The protection that vaccines provide against COVID-19 infection is mediated primarily by
Efficacy and safety of corticosteroids in patients with SARS-CoV-2 infection still are debated. Because large randomized clinical trials (RCTs) and a well-conducted meta-analysis on the use of corticosteroids, focused on patients with coronavirus disease (COVID-19) in intensive care units, recently were published, a meta-analysis of RCTs on corticosteroids therapy in patients with different disease severity
An international team of researchers has characterized the effect and molecular mechanisms of an amino acid change in the SARS-CoV-2 Spike protein N439K. Viruses with this mutation are both common and rapidly spreading around the globe. The peer reviewed version of the study appears January 25 in the journal Cell. Investigators found that viruses carrying this
In the United States alone, over 100,000 people are on the organ transplant list. Around 17 of these people will die per day without having received the transplant. It’s clear that organs from human donors will never be adequate for everyone looking for a transplant. Thus, scientists have been researching alternatives, such as using organs made from repurposed stem
Women and children bear substantial morbidity and mortality as a result of armed conflicts. This paper published in The Lancet focuses on the direct (due to violence) and indirect health effects of armed conflict on women and children (including adolescents) worldwide. It was estimate that nearly 36 million children and 16 million women were displaced
The Clalit Research Institute is currently examining the effect of the vaccine against the coronavirus developed by Pfizer. Preliminary data show that 14 days after the injection of the first vaccine, there is a real decrease in the rate of infection in the corona . The study compared the infection data of about 200,000 people aged 60 and over who
As of January 20, 2021, a total of 24,135,690 cases of coronavirus disease 2019 (COVID-19) and 400,306 associated deaths had been reported in the United States (https://covid.cdc.gov/covid-data-tracker/#cases_casesper100klast7days). On December 18, 2020, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for Moderna COVID-19 vaccine administered as 2 doses, 1 month apart to
Scientists at Children’s Hospital Los Angeles develop newer CAR T therapy that promises to be more effective and less toxic for children with neuroblastoma. Chimeric Antigen Receptor T-cell therapy—CAR T—has revolutionized leukemia treatment. Unfortunately, the therapy has not been effective for treating solid tumors including childhood cancers such as neuroblastoma. Preclinical studies using certain CAR
Following implementation of vaccination, reports of anaphylaxis after the first dose of the Pfizer-BioNTech COVID-19 vaccine emerged.Anaphylaxis is a life-threatening allergic reaction that occurs rarelyafter vaccination, with onset typically within minutes to hours.Notifications and reports of suspected severe allergic reactions and anaphylaxis following vaccination were captured in the Vaccine Adverse Event Reporting System (VAERS), the
Researchers in Cedars-Sinai Medical Center, Los Angeles found that the variant, originated in California, was present in more than half of samples tested last week by researchers in Los Angeles. In late December, scientists in California began searching coronavirus samples for a fast-spreading new variant that had just been identified in Britain. They found it, though in
The increased prevalence of obesity, diabetes and cardiovascular risk factors in people hospitalized with severe COVID-19 illness has engendered considerable interest in the metabolic aspects of SARS-CoV-2-induced pathophysiology. In this paper published in Cell Metabolism are updated concepts informing how metabolic disorders and their comorbidities modify the susceptibility to, natural history and potential treatment of
Virus-specific humoral and cellular immunity act synergistically to protect the host from viral infection. In this paper published on Cell Reports are interrogated the dynamic changes of virological and immunological parameters in 12 patients with symptomatic acute SARS-CoV-2 infection from disease onset to convalescence or death. SARS-CoV-2 viral RNA in the respiratory tract in parallel
Evidence is growing that self-attacking ‘autoantibodies’ could be the key to understanding some of the worst cases of SARS-CoV-2 infection. More than a year after COVID-19 emerged, many mysteries persist about the disease: why do some people get so much sicker than others? Why does lung damage sometimes continue to worsen well after the body
A new study found that antibodies in patients vaccinated against COVID-19 were able to neutralize a version of the new variant. Researchers tested 10 mutations of the B117 variant, which was first identified in the UK. The COVID-19 vaccine developed by BioNTech and Pfizer is likely to protect against the highly infectious variant of the virus, originally found
No definitive treatment for COVID-19 exists although promising results have been reported with remdesivir and glucocorticoids. Short of a truly effective preventive or curative vaccine against SARS-CoV-2, it is becoming increasingly clear that multiple pathophysiologic processes seen with COVID-19 as well as SARS-CoV-2 itself should be targeted. Because alpha-1-antitrypsin (AAT) embraces a panoply of biologic
SARS-CoV-2 501Y.V2, a novel lineage of the coronavirus causing COVID-19, contains multiple mutations within two immunodominant domains of the spike protein. In a paper recently published on https://www.biorxiv.org/content/10.1101/2021.01.18.427166v1.full.pdf it’s shown that this lineage exhibits complete escape from three classes of therapeutically relevant monoclonal antibodies. Furthermore 501Y.V2 shows substantial or complete escape from neutralizing antibodies in
At the heart of each coronavirus is its genome, a twisted strand of nearly 30,000 “letters” of RNA. These genetic instructions force infected human cells to assemble up to 29 kinds of proteins that help the coronavirus multiply and spread. As viruses replicate, small copying errors known as mutations naturally arise in their genomes. A lineage of coronaviruses will
What do we know about the new variant emerging from Brazil? This variant, known as P.1 or VOC202101/02 in the UK, was first detected in travellers from Brazil who arrived in Japan in January 2021. It involves 17 unique amino acid changes, three deletions, four synonymous mutations, and one 4nt insertion. It has several mutations
Research conducted by the University of Bari in collaboration with the Campus Bio-Medico University of Rome The studies carried out by the research team of the University of Bari in collaboration with the Campus Bio-Medico University of Rome, formed by Luigi Leonardo Palese, Anna Maria Sardanelli, and Camilla Isgrò of the Department of Basic Medical
A pair of new gene therapies promise a potentially lasting cure for sickle cell disease by subtly altering the genetic information in patients’ bone marrow cells, researchers report. Both therapies work by switching on a gene that promotes production of fetal hemoglobin, said Dr. Lewis Hsu, chief medical officer of the Sickle Cell Disease Association
COVID-19 tests that use patients’ saliva to screen for the virus are just as effective as those that use swabs collected from the nose and throat, an analysis published by JAMA Internal Medicine found. Saliva-based tests correctly identified those infected with the new coronavirus 83% of the time, while nose-throat swab tests were 85% accurate, the review of
On December 14, 2020, the United Kingdom reported a SARS-CoV-2 variant of concern (VOC), lineage B.1.1.7, also referred to as VOC 202012/01 or 20I/501Y.V1.* The B.1.1.7 variant is estimated to have emerged in September 2020 and has quickly become the dominant circulating SARS-CoV-2 variant in England (1). B.1.1.7 has been detected in over 30 countries,
The RECOVERY trial was established as a randomised clinical trial to test a range of potential treatments for COVID-19. Since May 2020, the RECOVERY trial has included a randomised comparison of convalescent plasma vs. usual care alone. Convalescent plasma has been widely used as a treatment for COVID-19 but to date there has been no
Despite the significant improvement in survival outcomes of multiple myeloma (MM) over the past decade, it remains an incurable disease. Patients with triple-class refractory MM have limited treatment options and a dismal prognosis. Chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen has transformed the treatment armamentarium of relapsed/refractory MM (RRMM), with unprecedented overall
Imbalances in type and volume of bacteria may also be implicated in ‘long COVID’ The variety and volume of bacteria in the gut, known as the microbiome, may influence the severity of COVID-19 as well as the magnitude of the immune system response to the infection, suggests research published online in the journal Gut. Imbalances in
EMA has received an application for conditional marketing authorisation (CMA) for a COVID-19 vaccine developed by AstraZeneca and Oxford University. The assessment of the vaccine, known as COVID-19 Vaccine AstraZeneca, will proceed under an accelerated timeline. An opinion on the marketing authorisation could be issued by 29 January during the meeting of EMA’s scientific committee for human medicines (CHMP), provided
A model developed by CDC researchers estimates that 59% of coronavirus cases in the United States are spread by asymptomatic carriers. Transmissions from individuals who have not yet begun to exhibit signs of infection account for 35% of that total, while transmissions from people who never develop symptoms make up the other 24%. A model
Exosomes are nano-sized extracellular vesicles secreted by all cells. Extensive research over recent years has now shown these vesicles to be important players in intercellular signalling and to have a role in tissue regeneration, immunomodulation and other biological functions. A lipid bilayer protects the exosome cargo of nucleic acids and proteins from degradation and permits
Pregnant women infected with SARS-CoV-2 appear to be at higher risk of developing severe cases of COVID-19 than infected women who are not pregnant. Yet newborns are mostly doing well. Reports indicate that only about 5 percent of babies born to COVID-19-infected mothers are themselves infected, and most newborns who test positive have mild or
Dozens of people being treated for COVID-19 at a Florida hospital last summer became additionally infected with a mysterious, often deadly fungus called Candida auris, a US government study said Friday. The multidrug-resistant yeast was first identified in Japan in 2009 and has been a top priority for the Centers for Disease Control and Prevention
COVID-19 patients admitted to intensive care in the early months of the pandemic were subject to a significantly higher burden of delirium and coma than is typically found in patients with acute respiratory failure. Choice of sedative medications and curbs on family visitation played a role in increasing acute brain dysfunction for these patients. That’s
Clinicians should consider prescribing intravenous tocilizumab following the criteria defined below for patients in intensive care. Intravenous sarilumab could be considered as an alternative (if available).Any provider organisation treating patients with this intervention will be required to assure itself that the internal governance arrangements have been completed before either medicine is prescribed. These arrangements may
Pfizer Inc. and BioNTech SE announced results from an in vitro study conducted by Pfizer and the University of Texas Medical Branch (UTMB) that shows the antibodies from people who have received the Pfizer-BioNTech COVID-19 vaccine effectively neutralize SARS-CoV-2 with a key mutation that is also found in two highly transmissible strains. The results were published
When we speak of variants we refer to differences in the sequence of the genome due to mutations. Strain is a variant in which changes in its biology are demonstrated (antigenicity, transmissibility, virulence,…). For now, let’s talk about variants. The evaluation of the new variants should answer these questions: Has the new variant appeared by
Impact on molecular tests remains low The U.S. Food and Drug Administration is alerting clinical laboratory staff and health care providers that the FDA is monitoring the potential impact of viral mutations, including an emerging variant from the United Kingdom known as the B.1.1.7 variant, on authorized SARS-CoV-2 molecular tests, and that false negative results
First gene therapy to receive full EU marketing authorization for eligible MLD patients. One-time treatment with Libmeldy has been shown to preserve motor and cognitive function. Orchard Therapeutics, a global gene therapy leader, and its research alliance partners Fondazione Telethon and Ospedale San Raffaele, today announced that the European Commission (EC) granted full (standard) market authorization
Using a recently developed DNA base-editing technique, researchers correct accelerating aging disorder. Researchers have successfully used a DNA-editing technique to extend the lifespan of mice with the genetic variation associated with progeria, a rare genetic disease that causes extreme premature aging in children and can significantly shorten their life expectancy. The study was published in the journal Nature, and was
Scientists regenerate parts of the skull affected by craniosynostosis, a common birth defect. Using stem cells to regenerate parts of the skull, scientists corrected skull shape and reversed learning and memory deficits in young mice with craniosynostosis, a condition estimated to affect 1 in every 2,500 infants born in the United States, according to the
ApoE4, a strong genetic risk factor for Alzheimer’s disease, has been associated with increased risk for severe COVID-19. However, it is unclear whether ApoE4 alters COVID-19 susceptibility or severity and the role of direct viral infection in brain cells remains obscure. In this paper, published in Cell Stem Cells, the Authors tested the neurotropism of
Therapies to interrupt the progression of early coronavirus disease 2019 (Covid-19) remain elusive. Among them, convalescent plasma administered to hospitalized patients has been unsuccessful, perhaps because antibodies should be administered earlier in the course of illness. In this paper, published on NEJM, the Authors conducted a randomized, double-blind, placebo-controlled trial of convalescent plasma with high
Corticosteroid therapy is now recommended as a treatment in patients with severe COVID-19. But one key question is how to objectively identify severely ill patients who may benefit from such therapy. In a paper just published on Cell Metabolism, 12,862 COVID-19 cases from 21 hospitals in Hubei Province were equally assigned to a training and
The proximal origins of SARS-CoV and MERS-CoV from civets and camels, respectively, are well documented. Few genetic changes in these viruses are required for the interspecies transfers to humans. While precise details and timing of the evolutionary pathways remain to be elucidated, it is also apparent that SARS-CoV-2 emerged from the Sarbecovirus subgenus of the
SARS-CoV-2, the virus that causes COVID-19, has had a major impact on human health globally; infecting a large number of people; causing severe disease and associated long-term health sequelae; resulting in death and excess mortality, especially among older and vulnerable populations; interrupting routine healthcare services; disruptions to travel, trade, education and many other societal functions;
Does it spread more easily? Make people sicker? Mean that treatments and vaccines won’t work? Questions are multiplying as fast as new variants of the coronavirus, especially the one moving through England and now popping up in the U.S. and other countries. Scientists say there is reason for concern and more to learn but that
In an in-depth study of how COVID-19 affects a patient’s brain, National Institutes of Health researchers consistently spotted hallmarks of damage caused by thinning and leaky brain blood vessels in tissue samples from patients who died shortly after contracting the disease. In addition, they saw no signs of SARS-CoV-2 in the tissue samples, suggesting the
The new vaccine has been approved today after meeting the required safety, quality and effectiveness standards. The COVID-19 vaccine developed by Oxford University/AstraZeneca has today been given regulatory approval by the Medicines and Healthcare products Regulatory Agency (MHRA) after meeting required safety, quality and effectiveness standards. Following a rigorous, detailed scientific review by the MHRA’s
Severe coronavirus disease 2019 (COVID-19) is characterized by the intense formation of neutrophil extracellular traps (NETs), leading to the occlusion of microvessels, as shown in pulmonary samples. The occurrence of ST-elevated myocardial infarction (STEMI) is a serious cardiac manifestation of COVID-19; the intrinsic mechanism of coronary thrombosis appears to still be unknown. Objective of the
Children get sick less often than adults due to Covid-19, but children are at risk. This is the key insight from a paper in the Journal of American Medical Association (JAMA), a peer-reviewed medical journal, as the year draws to an end. The paper summarizes the current understanding of how children are affected by Covid-19. So far
Vaccines typically require years of research and testing before reaching the clinic, but in 2020, scientists embarked on a race to produce safe and effective coronavirus vaccines in record time. Researchers are currently testing 64 vaccines in clinical trials on humans, and 19 have reached the final stages of testing. At least 85 preclinical vaccines are under active
The SARS-CoV-2 spike (S) protein is the target of vaccine design efforts to end the COVID-19 pandemic. Despite a low mutation rate, isolates with the D614G substitution in the S protein appeared early during the pandemic, and are now the dominant form worldwide. In this paper are explored spike conformational changes and the effects of
The SARS-CoV-2 pandemic poses an unprecedented public health crisis. Evidence suggests that SARS-CoV-2 infection causes dysregulation of the immune system. However, the unique signature of early immune responses remains elusive. In this paper the transcriptome of rhesus macaques and mice infected with SARS-CoV-2 was characterized. Alarmin S100A8 was robustly induced in SARS-CoV-2 infected animal models
Recently a distinct phylogenetic cluster (named lineage B.1.1.7) was detected within the COG-UK surveillance dataset. This cluster has been growing rapidly over the past 4 weeks and since been observed in other UK locations, indicating further spread. Several aspects of this cluster are noteworthy for epidemiological and biological reasons and we report preliminary findings below.
There’s a growing variety and availability of tests related to SARS-CoV-2. All types of tests can help healthcare providers make more accurate diagnosis, support better management of individual patients and provide better guidance to manage population risk. Active infection is detected with RT-PCR tests detect the presence of SARS-CoV-2 based on its genetic make up (RNA). These tests
Adults 45 years or older were more likely to die from COVID-19 during those months than from chronic lower respiratory disease, transport accidents (eg, motor vehicle fatalities), drug overdoses, suicide, or homicide. In contrast, for individuals younger than age 45 years, other causes of death, such as drug overdoses, suicide, transport accidents, cancer, and homicide
“Thanks to this technology and to the specific fighting capabilities of these cells, extraordinary results have been obtained: The therapy is a new hope for patients who no longer responded to other treatments. The therapy seems to have a long-lasting effect after a single application Unlike many other therapies, which benefit only a small portion
Targeting endothelial cells –cells that comprise the blood vessel wall which regulate oxygen exchange between airways and the bloodstream– may be a novel approach restoring normal lung function to Covid-19 patients with serious lung disease. This hypothesis stems from a study by researchers in the Department of Microbiology and Immunology in the Renaissance School of
There are lots of useful online resources to learn about COVID-19 and some of the clinical studies taking place across the country. What’s been missing is a one-stop online information portal that pulls together the most current information for people of all groups, races, ethnicities, and backgrounds who want to get involved in fighting the
The CLI study is unlikely to meet its primary endpoint by the time of the final analysis Substantial low number of events in the placebo group in the CLI study decreased the statistical power of the study to meet its primary endpoint PLX-PAD was well tolerated, and no safety concerns were raised Company to terminate the CLI study to focus on different therapeutic areas in its pipeline and expects three clinical readouts within the coming calendar year
CALCULATOR GENERATES MORTALITY RISK ESTIMATES FOR INDIVIDUALS AND COMMUNITIES BASED ON SOCIODEMOGRAPHIC INFO AND MEDICAL HISTORY A new online calculator for estimating individual and community-level risk of dying from COVID-19 has been developed by researchers at the Johns Hopkins Bloomberg School of Public Health. The researchers who developed the calculator expect it to be useful to
Potential treatments for Covid-19 have been identified after the discovery of five genes associated with the most severe form of the disease. Genetic evidence is second only to clinical trials as a way to tell which treatments will be effective in a disease. Existing drugs that target the actions of the genes reveal which drugs
During the coronavirus disease 2019 (COVID-19) pandemic, the general public has been advised to wear masks or improvised face coverings to limit transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, there has been considerable confusion and disagreement regarding the degree to which masks protect thewearer from airborne particles. To evaluate the fitted filtration
World Health Organization expert groups recommended mortality trials of four repurposed antiviral drugs (remdesivir, hydroxychloroquine, lopinavir and interferon beta-1a) in patients hospitalized with Covid-19. Inpatients with Covid-19 were randomly assigned equally between one of the trial drug regimens that was locally available and open control (up to five options, four active and the local standard
In a 17-4 vote, with one abstention, a panel of advisers to the Food and Drug Administration recommended Thursday that the COVID-19 vaccine being developed by Pfizer and BioNTech be authorized for emergency use during the coronavirus pandemic. The vote in favor of the vaccine was taken to answer the agency’s question: Do the benefits
Previous studies reported on the safety and applicability of mesenchymal stem/stromal cells (MSCs) to ameliorate pulmonary inflammation in acute respiratory distress syndrome (ARDS). Thus, multiple clinical trials assessing the potential of MSCs for COVID-19 treatment are underway. Yet, as SARS-inducing coronaviruses infect stem/progenitor cells, it is unclear whether MSCs could be infected by SARS-CoV-2 upon
COVID-19, the common cold, seasonal allergies and the flu have many similar signs and symptoms. Find out about some of the important differences between these illnesses. If you have signs or symptoms of coronavirus disease 2019 (COVID-19), it’s important that you contact your doctor or clinic right away for medical advice. But COVID-19, the common cold,
Sex should be considered an important biological factor when designing therapies and vaccination strategies for COVID-19. Global-scale collaboration between scientists has taken on new forms in the midst of the COVID-19 pandemic, with connection underpinning the work. A paper investigating the role of sex in patients infected with COVID-19 is the result of a partnership between researchers
When a coronavirus—including SARS-CoV-2, which causes COVID-19—infects someone, it hijacks the person’s cells, co-opting their molecular machinery for its own survival and spread. Researchers at Gladstone Institutes and the Chan Zuckerberg Biohub, in collaboration with scientists at UC San Francisco (UCSF) and Synthego Corporation, have identified critical molecular processes in human cells that coronaviruses use
The Janssen Pharmaceutical Companies of Johnson & Johnson unveils longer-term results from the combined Phase 1b/2 CARTITUDE-1 study evaluating ciltacabtagene autoleucel (cilta-cel) for the treatment of patients with relapsed and/or refractory multiple myeloma. Cilta-cel is an experimental BCMA-directed (B cell maturation antigen) chimeric antigen receptor T cell (CAR-T) therapy. Data presented at the ongoing Annual Meeting
2020 has been a difficult year for all, but has seen 58 vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) be developed and in clinical trials, with some vaccines reportedly having more than 90% efficacy against COVID-19 in clinical trials. This remarkable achievement is much-needed good news as COVID-19 cases are currently at their
A team of scientists from Gladstone, UC Berkeley, and UC San Francisco outlined the technology for a rapid, one-step mobile test that could help combat the pandemic and fully reopen communities. Imagine swabbing your nostrils, putting the swab in a device, and getting a read-out on your phone in 15 to 30 minutes that tells
Earlier this year, Caron Jacobson, MD, presented the interim analysis of ZUMA-5: A phase 2 study of axicabtagene ciloleucel in patients with relapsed/refractory indolent non-Hodgkin lymphoma. Results from that interim analysis showed that the vast majority of patients with follicular lymphoma or marginal zone lymphoma – two slow-growing forms of non-Hodgkin lymphoma – responded to and
Vaccine “has the potential to provide durable humoral immunity” against virus, NIAID authors argue Antibody responses to Moderna’s COVID-19 vaccine candidate, mRNA-1273, remained strong for almost 4 months following vaccination, data from a phase I trial indicated. Serum neutralizing antibodies were detected in 34 healthy adult volunteers at day 119 following the first dose, and
Vaccines against covid could give “superhuman immunity”, stronger than if the disease is passedThe researchers Dennis Burton and Eric Topol have published in ‘Nature’ a correspondence in which they address the perspectives of the immunity of vaccines, comparing the available data on covid vaccines with those on vaccines against other diseases. They are optimistic that
The coronavirus can reach the human brain after it is inhaled through a person’s nose and becomes trapped in the nasal mucus, a study found. It is the first known evidence that the coronavirus can infect neurons of the brain through the mucosal pathway. In the course of the pandemic, it has become clear that
PAK4 inhibitor improved T cell infiltration and shrank solid tumors in mice The labyrinth of jumbled blood vessels in the tumor microenvironment remains one of the toughest blockades for cellular therapies to penetrate and treat solid tumors. Now, in a new study published online today in Nature Cancer, Penn Medicine researchers found that combining chimeric antigen receptor (CAR)
Analysis of 135,000+ medical records shows the novel coronavirus hits hardest among teens, children with diabetes or cancer, lower-income families, and Black, Latin and Asian groups. In the most comprehensive analysis to date of U.S. children tested and treated for COVID-19, an organization representing seven of the nation’s largest pediatric medical centers reports that some
Combining Machine Learning with Cell Engineering, Scientists Can Design ‘Living Medicines’ that Precisely Target Tumors Finding medicines that can kill cancer cells while leaving normal tissue unscathed is a Holy Grail of oncology research. In two new papers, scientists at UC San Francisco and Princeton University present complementary strategies to crack this problem with “smart”
Hundreds of trials are under way, 3 CAR T-cell therapies for hematologic malignancies are on the market, and 2 new products may receive FDA approval in the next several months, including a BCMA–directed therapy that is poised to help transform treatment of multiple myeloma Research on chimeric antigen receptor (CAR) T-cell therapies has exploded since
Convalescent plasma is frequently administered to patients with Covid-19 and has been reported, largely on the basis of observational data, to improve clinical outcomes. Minimal data are available from adequately powered randomized, controlled trials. In this paper researchers of the Clinical Pharmacology Section, Hospital Italiano de Buenos Aires, Juan D. Perón, Buenos Aires, Argentina as
Discovery represents a major milestone for regenerative medicine that could help more people benefit from stem cell therapy. Scientists at Sanford Burnham Prebys Medical Discovery Institute have created a drug that can lure stem cells to damaged tissue and improve treatment efficacy—a scientific first and a major advance for the field of regenerative medicine. The
As of September, the vast majority of Americans did not have coronavirus antibodies, according to a new study published in JAMA Internal Medicine. These data matter as the coronavirus spreads rapidly throughout most of the country, most people remain vulnerable to it. Across the U.S., the portion of states’ populations with detectable antibodies ranged from less
COVID-19 caused by SARS-COV2 infection can lead to multi-organ injuries and significant mortality in severe and critical patients, especially among those individuals with type 2 diabetes (T2D) as a comorbidity. While attenuated mortality was observed with aggressive glucose control, it was unclear whether therapeutic regiments including insulin treatment was beneficial for patients with COVID-19 and
The SARS-CoV-2 virus is causing a global pandemic and cases continue to rise. Most infected individuals experience mildly symptomatic coronavirus disease 2019 (COVID-19), but it is unknown whether this can induce persistent immune memory that could contribute to immunity. In this paper, published on Cell, it’s performed a longitudinal assessment of individuals recovered from mild
Early reports indicated that in COVID-19 may be associated with coagulation dysfunction. Studies have reported varying rates of thromboembolism. In this paper, the Authors searched PubMed, Cochrane and Embase for systematic reviews and meta-analyses evaluating thromboembolism rates in COVID-19 published until June 12, 2020. The search terms were “COVID-19”, “SARS-CoV-2” or “novel coronavirus” and “venous
The ChAdOx1 nCov-2019 coronavirus vaccine, developed by teams at the University of Oxford, has been shown to trigger a robust immune response in healthy adults aged 56-69 and those over 70 years of age. The data, published in The Lancet, suggest that one of the groups most vulnerable to serious illness, and death from COVID-19, could build
Combinational antigen recognition is the most logical way to improve the safety of cancer therapy. CAR T cells therapy, combined with synthetic biology, protein engineering, and bioinformatics, can perform advanced computations to enhance tumor targeting specificity. Immunotherapy, including biologic and cellular approaches, is a critical area of focus for cancer therapeutics. Of the methodologies used
The rheumatoid arthritis drug baricitinib can block viral entry and reduce mortality in patients with moderate to severe COVID-19, according to translational research by an international team coordinated by researchers from Karolinska Institutet in Sweden. The findings, published in the journal Science Advances, support the continuation of ongoing randomized clinical trials. “We are pleased to
As of 20 November 2020, the number of COVID-19 cases was reported to be more than 57 million, leading to more than 1.361,000 deaths worldwide . Elevated levels of CRP, cytokine and chemokines, together with low lymphocyte and eosinophil counts, characterize patients with severe disease. However, a reliable biomarker of poor outcome in COVID-19 is
Immunologists have determined the process driving life-threatening inflammation, lung damage and organ failure in patients with COVID-19, sepsis and other inflammatory disorders suggesting possible treatment using existing drugs. The COVID-19 pandemic continues to cause significant illness and death while treatment options remain limited.St. Jude Children’s Research Hospital scientists have discovered a potential strategy to prevent life-threatening
Primary efficacy analysis demonstrates BNT162b2 to be 95% effective against COVID-19 beginning 28 days after the first dose;170 confirmed cases of COVID-19 were evaluated, with 162 observed in the placebo group versus 8 in the vaccine group Efficacy was consistent across age, gender, race and ethnicity demographics; observed efficacy in adults over 65 years of
State-level reports are the best publicly available data on child COVID-19 cases in the United States. The American Academy of Pediatrics and the Children’s Hospital Association are collaborating to collect and share all publicly available data from states on child COVID-19 cases (definition of “child” case is based on varying age ranges reported across states;
Conventional wisdom has it that too many cooks spoil the broth. But such judiciousness is not usually considered the basis for scientific pronouncements or international rulings on the need to limit the number of people in kitchens. But, when it comes to video games, conventional wisdom, not science, forms the basis for our thinking and
Over the last decade, chimeric antigen receptor (CAR)-T cell therapy has emerged as a promising treatment modality for relapsed/refractory B-cell malignancies in both children and adults. As an adoptive immune therapy, CAR-T cells have the potential to overcome disease that is resistant to chemoand radiotherapy as well as represent a viable option for those who
An independent data and safety monitoring board (DSMB) overseeing the Phase 3 trial of the investigational COVID-19 vaccine known as mRNA-1273 reviewed trial data and shared its interim analysis with the trial oversight group on Nov. 15, 2020. This interim review of the data suggests that the vaccine is safe and effective at preventing symptomatic
Key points: Researchers have analysed immune cell types and numbers from the blood of healthy volunteers, COVID-19 patients experiencing mild-to-moderate effects and patients classified as severe to understand whether particular characteristics of their immune system response can identify treatment targets or indicate disease severity. After comparing the T cell immune response, the researchers noted the
Diabetes is associated with increased mortality from Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). Given literature suggesting a potential association between SARS-CoV-2 infection and diabetes induction, it was examined pancreatic expression of angiotensin-converting enzyme-2 (ACE2), the key entry factor for SARS-CoV-2 infection. Specifically, in this paper published on Cell Metabolism, were analyzed five public scRNA-seq pancreas
The rapid spread of SARS-CoV-2, the causative agent of Coronavirus disease 2019 (COVID-19), has been accompanied by the emergence of distinct viral clades, though their clinical significance remains unclear. In this paper it’s investigated the phylogenetic characteristics of SARS-CoV-2 infections in Chicago, Illinois, and assessed their relationship to clinical parameters. Whole-genome sequencing of SARS-CoV-2 isolates
It’s been a tough couple of weeks for immune-based therapies for COVID-19. We know that immune modulation in this disease, especially in its most severe manifestations, can improve outcomes. Favorable results from the RECOVERY study of dexamethasone have made it the standard of care for most hospitalized patients who require oxygen. And we also know that our own immune
Effective, Early Interventions would Benefit Individual Patients and Healthcare System COVID-19 treatments for people with early infection are needed urgently, according to a JAMA Viewpoint article by NIAID Director Anthony S. Fauci, M.D., and colleagues. Treating people early in the course of infection with SARS-CoV-2, the virus that causes COVID-19, would speed their recovery, reduce
SARS-CoV-2 spike (S) mediates viral entry into cells and is critical for vaccine development against COVID-19. Structural studies have revealed distinct conformations of S, but real-time information that connects these structures, is lacking. In this paper it’s applied single-molecule Fluorescence (Förster) Resonance Energy Transfer (smFRET) imaging to observe conformational dynamics of S on virus particles.
An inhaled form of interferon — a drug commonly used to treat multiple sclerosis by injection — may help protect hospitalized Covid-19 patients from getting worse, according to a British drugmaker. Results were first released in July, but were published Thursday as a peer-reviewed study in The Lancet Respiratory Medicine. The body naturally releases interferon when
An obsessive compulsive disorder (OCD) drug may help improve the conditions of coronavirus patients, a new study suggests. Fluvoxamine, sold under the brand name Luvox, is a medication that scientists believe has anti-inflammatory properties, which can help control the immune system’s overreaction to the virus. No patient who was given the drug suffered from shortness of breath
To understand the usual approval process followed by the FDA, researchers of the Yale University School of Medicine have systematically evaluated all novel vaccines approved by the FDA over the last decade, characterizing the premarket development and regulatory review times, the clinical evidenceon which approval was based, and the size and follow-up duration of the
The U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the investigational monoclonal antibody therapy bamlanivimab for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients. Bamlanivimab is authorized for patients with positive results of direct SARS-CoV-2 viral testing who are 12 years of age and older weighing at least 40 kilograms (about
SARS-CoV-2 induced hypercytokinemia and inflammation are critically associated with COVID19 disease severity. Baricitinib, a clinically approved JAK1/2 inhibitor, is currently being investigated in COVID-19 clinical trials. In this paper published on Cell, are investigated the immunologic and virologic efficacy of baricitinib in a rhesus macaque model of SARS-CoV-2 infection. Viral shedding measured from nasal and
A National Institutes of Health clinical trial evaluating the safety and effectiveness of hydroxychloroquine for the treatment of adults with coronavirus disease 2019 (COVID-19) has formally concluded that the drug provides no clinical benefit to hospitalized patients. Though found not to cause harm, early findings in June when the trial was stopped indicated that the
Remdesivir is an antiviral medication that targets a range of viruses. It was originally developed over a decade ago to treat hepatitis C and a cold-like virus called respiratory syncytial virus (RSV). Remdesivir wasn’t an effective treatment for either disease. But it showed promise against other viruses. Researchers tested remdesivir in clinical trials during the
Scientists at University of Cambridge have used gene therapy to regenerate damaged nerve fibres in the eye, in a discovery that could aid the development of new treatments for glaucoma, one of the leading causes of blindness worldwide. Axons – nerve fibres – in the adult central nervous system (CNS) do not normally regenerate after
Investigations of deceased COVID-19 patients have shed light on possible lung damage caused by the virus. The study, published today in The Lancet’s eBioMedicine, by King’s in collaboration with University of Trieste and the International Centre for Genetic Engineering and Biology in Italy, shows the unique characteristics to the SARS-CoV-2 virus and may explain why
A new study reveals the virus triggers production of antibodies circulating through the blood, causing clots in people hospitalized with the disease. Blood clots continue to wreak havoc for patients with severe COVID-19 infection, and a new study explains what may spark them in up to half of patients. The culprit: an autoimmune antibody that’s
Integrated analysis revealed a positive correlation of coagulopathy withcytokine storm in COVID-19-infected patients; the D-dimer rises early, which indicates that coagulopathy acts as a prodrome of cytokine storm. Coagulopathy can be used to monitor early cytokine storm in COVID-19-infected patients. Coagulopathy appeared around a few days in advance of a cytokine storm. It was also
Hospitalized Patients Who Were Taking Daily Aspirin Had Lower Risk of ICU Admission, Ventilation, and Dying from the Virus Hospitalized COVID-19 patients who were taking a daily low-dose aspirin to protect against cardiovascular disease had a significantly lower risk of complications and death compared to those who were not taking aspirin, according to a new
Targeting cells’ ‘trash compactor’ could lead to new antiviral strategy to fight COVID-19. Researchers at the National Institutes of Health have discovered a biological pathway that the novel coronavirus appears to use to hijack and exit cells as it spreads through the body. A better understanding of this important pathway may provide vital insight in
In a Commentary on EBioMedicine researchers of Icahn School of Medicine at Mount Sinai, New York try to solve the enigma between dead viral particles testing or real clinical reinfection. Nine months after the first reports describing a novel corona virus (Severe Acute Respiratory Syndrome coronavirus 2, SARS-CoV-2) causing severe disease in humans (coronavirus Disease
B cell acute lymphoblastic leukemia (B-ALL) blasts hijack the bone marrow (BM) microenvironment to form chemoprotective leukemic BM “niches,” facilitating chemoresistance and, ultimately, disease relapse. However, the ability to dissect these evolving, heterogeneous interactions among distinct B-ALL subtypes and their varying BM niches is limited with current in vivo methods. In this paper , New
Researchers from the University of Kent, the Goethe-University in Frankfurt am Main (Germany), and the Hannover Medical School (Germany) have identified a drug with the potential to provide a treatment for COVID-19. The international team led by Professor Martin Michaelis, Dr. Mark Wass (both School of Biosciences, University of Kent), and Professor Jindrich Cinatl (Institute
The COVID infection fatality ratio is around 1% in high-income countries, but substantially lower in low-income countries with younger populations. These are the findings of a new report from the Imperial College London COVID-19 Response Team. The report reveals that: In high income countries, the estimated overall infection fatality ratio (IFR) is 1.15% (95% prediction interval
Lower back pain caused by degenerative disc disorder affects approximately 40% of the population over 40 and though many of us may never experience adverse effects from the disorder, it is the cause of chronic back pain for numerous Americans. Recent imaging diagnostics and cellular based direct-injection therapeutics for degenerative disc and spinal cord injuries
Sensor data from wearable devices can complement virus testing and conventional screening to signal new infections. Examining data from the first six weeks of their landmark DETECT study, a team of scientists from the Scripps Research Translational Institute sees encouraging signs that wearable fitness devices can improve public health efforts to control COVID-19. The DETECT study, launched
The ISB-Swedish COVID-19 Immune Response Study has revealed new findings that suggest that treatments aimed at arresting the infection at the stage of moderate severity may be most effective. The symptoms of COVID-19 vary widely, from very mild to severe conditions requiring ICU care. Researchers comprehensively studied a large number of patients during the week
Researchers from the National Institutes of Health (NIH) have discovered a new inflammatory disorder called vacuoles, E1 enzyme, X-linked, autoinflammatory and somatic syndrome (VEXAS), which is caused by mutations in the UBA1 gene. VEXAS causes symptoms that included blood clots in veins, recurrent fevers, pulmonary abnormalities and vacuoles (unusual cavity-like structures) in myeloid cells. The scientists reported
In patients with critical manifestations of COVID-19, life-threatening complications such as ARDS and multiple organ dysfunction are mediated by extensive inflammation, neutrophils recruitment, cytokine storm syndrome and dysregulated immune innate responses. MSCs because of their immunomodulatory, regenerative, and antimicrobial properties could render several therapeutic effects in the setting of COVID-19. While data from countless clinical
Phase 1 Clinical Study will Evaluate ADI-001 Safety and Efficacy in Patients with B-cell non-Hodgkin’s lymphoma Adicet Bio, Inc., a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for ADI-001,
The emergence of a novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) caused a major disease outbreak that posed a threat to public health worldwide. Among the western countries, Italy was the first to experience a vast Coronavirus Disease 2019 (COVID-19) outbreak and the province of Bergamo experienced the deadliest COVID-19 outbreak in theworld. Due
NIH-funded therapy will now be tested in humans A newly developed light-sensing protein called the MCO1 opsin restores vision in blind mice when attached to retina bipolar cells using gene therapy. The National Eye Institute, part of the National Institutes of Health, provided a Small Business Innovation Research grant to Nanoscope, LLC for development of
Even if state-level governments in the United States reimpose limited social distancing measures to halt the spread of COVID-19, the death toll could more than double by the end of February 2021 to 511,000, according to projections released Friday. Near-universal mask wearing over the coming months could reduce that grim tally by nearly 130,000, researchers
Scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) have discovered that neutrophils, the most abundant cells of the innate immune system, have many more functions in the body than previously thought. This finding suggests possible new treatments for many diseases, including cancer. In a study published in the journal Cell, the research team demonstrates that
Researchers have identified a second receptor that might be important in SARS-CoV-2 infectivity, according to a new report published in Science on October 20. This cofactor helps facilitate virus-host cell interactions in cells with low levels of angiotensin-converting enzyme 2 (ACE2), the primary receptor on host cells, and might explain the increased pathogenicity of SARS-CoV-2. Why is
Convalescent plasma may not prevent progression to severe disease or reduce mortality risk in hospitalized patients with moderate COVID-19, based on a phase 2 trial involving more than 400 patients in India. The PLACID trial offers real-world data with “high generalizability,” according to lead author Anup Agarwal, MD, of the Indian Council of Medical Research,
Coronavirus disease-19 (COVID-19), caused by the SARS-CoV-2 virus, leads to respiratory symptoms that can be fatal. However, neurological symptoms have also been observed in some patients. The cause of these complications is currently unknown. In this paper, were use human pluripotent stem cell-derived brain organoids to examine SARS-CoV-2 neurotropism. Was found expression of viral receptor
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today launched a study designed to determine whether certain approved therapies or investigational drugs in late-stage clinical development show promise against COVID-19 and merit advancement into larger clinical trials. The ACTIV-5 Big Effect Trial, which will enroll adult volunteers hospitalized
A number of investigational agents and drugs that are approved for other indications are currently being studied in clinical trials for the treatment of COVID-19 and associated complications. Data from randomized controlled trials, prospective and retrospective observational cohorts, and case series studies are rapidly emerging. The COVID-19 Treatment Guidelines Panel (the Panel) continues to review
Last Updated: October 9, 2020 Plasma from donors who have recovered from COVID-19 may contain antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that may help suppress the virus and modify the inflammatory response.1 Recommendation There are insufficient data for the COVID-19 Treatment Guidelines Panel (the Panel) to recommend either for or against the
No reductions seen in 28-day mortality or duration of hospital stay in COVID-19 with lopinavir-ritonavir. Lopinavir-ritonavir is not associated with reductions in 28-day mortality or duration of hospital stay among patients admitted to the hospital with COVID-19, according to a study published online Oct. 5 in The Lancet. Peter W. Horby, M.D., Ph.D., and colleagues on
Was compared the US to Organisation for Economic Co-operation and Development countries with populations exceeding 5million and greater than $25 000 per capita gross domestic product. For each country, was calculated the COVID-19 per capita mortality rate and grouped countries by mortality: (1) low (COVID-19 deaths, <5/100 000), (2) moderate (5-25/ 100 000), and (3)
In the past three decades the field of gene therapy has made remarkable progress surging from mere laboratory experiments to FDA-approved products which bring significant reduction in disease burden to patients who previously had no therapeutic options for their serious conditions. In this paper it’s reviewed the evolution of the gene therapy clinical research landscape
Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) infection is associated with hypercoagulability caused by direct invasion of endothelial cells and\or proinflammatory cytokine release. Thromboprophylaxis with enoxaparin is recommended by current guidelines, but evidence is still weak. The aim of this study was to assess the impact of thromboprophylaxis with enoxaparin on hospital mortality in patients
The RESTORE position paper represents the cumulative efforts of the RESTORE community, and the steering committee since the start of the RESTORE initiative in 2019. It outlines, in depth, the RESTORE view on why Europe should invest in Advanced Therapies, the roadblocks in Advanced Therapy development and implementation into patient care, and makes recommendations about
A new paper published on EBioMedicine analyzes metagenome contribution to Covid-19 response variability. A key question concerning COVID-19 is why most infected persons do not develop severe disease, while others become critically ill. This dichotomy is related to age, gender, immunosuppression and comorbidities, but many persons who are young succumb to the virus. A significant
The COVID-19 pandemic has led to extensive morbidity and mortality throughout the world. Clinical features that drive SARS-CoV-2 pathogenesis in humans include inflammation and thrombosis, but the mechanistic details underlying these processes remain to be determined. In this study, was demonstrated endothelial disruption and vascular thrombosis in histopathologic sections of lungs from both humans and
SARS-CoV-2 is a recently identified coronavirus that causes the respiratory disease known as COVID-19. Despite the urgent need, it’s not fully understood the molecular basis of SARS-CoV-2 pathogenesis. In this paper, are comprehensively defined the interactions between SARS-CoV-2 proteins and human RNAs. NSP16 binds to the mRNA recognition domains of the U1 and U2 splicing
RNA-Seq and high-resolution mass spectrometry on 128 blood samples from COVID-19 positive and negative patients with diverse disease severities and outcomes were performed and published on Cell Systems Quantified transcripts, proteins, metabolites, and lipids were associated with clinical outcomes in a curated relational database, uniquely enabling systems analysis and cross-ome correlations to molecules and patient
Interleukin-6 signal blockade showed preliminary beneficial effects in treating inflammatory response against SARS-CoV-2 leading to severe respiratory distress. In this paper, published on EClinicalMedicine are described the outcomes of off-label intravenous use of Sarilumab in severe SARS-CoV-2-related pneumonia. 53 patients with SARS-CoV-2 severe pneumonia received intravenous Sarilumab; pulmonary function improvement or Intensive Care Unit (ICU)
The contribution of CD4 + T cells to protective or pathogenic immune responses to SARS-CoV-2 infection remains unknown. In this paper it’s presented single-cell transcriptomic analysis of >100,000 viral antigen-reactive CD4 + T cells from 40 COVID-19 patients. In hospitalized patients compared to non-hospitalized patients, were found increased proportions of cytotoxic follicular helper (T FH
The more common manifestation in the COVID-19 era may be HFpEF related primarily to the unmasking of subclinical HFpEF and secondarily to the development of new HFpEF following infection with SARS-CoV-2. Patients with preexisting cardiovascular disease (CVD) who develop coronavirus disease 2019 (COVID-19) have worse outcomes than patients without CVD.Infection with severe acute respiratory syndrome
Fewer than 10 percent of the U.S. adult population formed antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the first wave of the pandemic, according to a study published online Sept. 25 in The Lancet. Shuchi Anand, M.D., from the Stanford University School of Medicine in Palo Alto, California, and colleagues conducted a cross-sectional
In this randomized clinical trial, although limited by early termination, there was no clinical benefit of hydroxychloroquine administered daily for 8 weeks as pre-exposure prophylaxis in hospital-based HCWs exposed to patients with COVID-19. Despite promising early reports and strong in vitro performance, Hydroxychloroquine (HCQ) has become the major therapeutic disappointment of the COVID pandemic. Research
Research in England shows a dangerous relationship between the viruses that cause both diseases; for those in the ICU with co-infection, the risk of death is 6.33 times higher. People infected at the same time by the new coronavirus and the flu virus are twice as likely to die than those infected by Sars-Cov-2 alone . This is the
Two categories of disease are interacting within specific populations—infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and an array of non-communicable diseases (NCDs). These conditions are clustering within social groups according to patterns of inequality deeply embedded in our societies. The aggregation of these diseases on a background of social and economic disparity exacerbates
Early in the pandemic, other clinicians noted that even some patients who didn’t have preexisting heart conditions experienced cardiovascular damage while fighting COVID-19 infections, pointing to a possible causative link. Researchers had found, for example, that 8–12 percent of hospitalized COVID-19 patients had elevated levels of muscle contraction–regulating proteins called troponins—a sign of heart damage—and that these
Currently, no Food and Drug Administration (FDA)-approved therapeutics exist for coronavirus disease 2019 (COVID-19). In this context, the pandemic has put considerable pressure on health care providers to prescribe treatments despite limited information about their safety and efficacy. This pressure has exacerbated the tension between the importance of practicing evidence-based medicine and the urgency of
New findings by scientists at the National Institutes of Health and their collaborators help explain why some people with COVID-19 develop severe disease. The findings also may provide the first molecular explanation for why more men than women die from COVID-19. The researchers found that more than 10% of people who develop severe COVID-19 have
Children were less likely than adults to acquire a COVID-19 infection from an index case, a meta-analysis found. Across 32 contact tracing or population testing studies comparing SARS-CoV-2 prevalence in children and adults, children younger than 14 were less likely to be infected from an index case overall (odds ratio 0.56, 95% CI 0.37-0.85), and
COVID-19 appears to have significant extrapulmonary complications affecting multiple organ systems. Critically ill patients with COVID-19 oftendevelop gastrointestinal complications during their hospital stay, including bowel ischemia, transaminitis, gastrointestinal bleeding, pancreatitis, Ogilvie syndrome, and severe ileus. Whether the high incidence of gastrointestinal complications is a manifestation of critical illness in general or is specific to COVID-19
Chimeric antigen receptor (CAR) technology and its application to regulatory T cells (Tregs) has garnered interest among researchers in the field of cell and gene therapy. Merging the benefits of CAR technology with Tregs offers a novel and promising therapeutic option for durable reshaping of undesired immune responses following solid organ or hematopoietic stem cell
They are relatively common so may act as important driver of viral spread, warn researchers People with ‘silent’ COVID-19 infection have as much coronavirus in their noses and throats as those with symptoms, reveals research published online in the journal Thorax. Given how many of these people there are—a fifth of those infected, the study findings show–they may
Despite the first clinical studies reporting on a correlation betweenthe migration potential of transplanted stem cells and their therapeutic efficacy, it is unclear if effective stem cell therapies requirereliable and sufficient delivery of the cells to the desired anatomiclocations, as well as survival of the cellular graft. Moreover, the many complex processes involved in stem
First-of-its kind study to be supported by the Cura Foundation, The Marcus Foundation, Sanford Health and Alliance for Cell Therapy Now The Cura Foundation in collaboration with The Marcus Foundation, Sanford Health and Alliance for Cell Therapy Now, is supporting a clinical trial of human cord tissue mesenchymal stromal cells (hCT-MSC) to treat children with
The frequency of children carrying asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been suggested to be higher than among adults. It is also suggested that asymptomatic children enhance viral spread. A research letter by published in the journal JAMA Pediatrics in September 2020 explores the truth of this common belief. Earlier Research Earlier studies
In a paper published on EClinicalMedicine, has been assessed outcome of patients with moderate and severe COVID-19 following treatment with convalescent plasma (CP) and the association with IgG levels in transfused CP. A prospective cohort study. Primary outcome was improvement at day 14 defined as alive, not on mechanical ventilation, and moderate, mild, or recovered
The SARS-CoV-2 spike (S) protein variant D614G supplanted the ancestral D614 virus worldwide, reaching near fixation in a matter of months. In this paper on Cell it’s shown that D614G was more infectious than the ancestral form on human lung cells, colon cells, and on cells rendered permissive by ectopic expression of human ACE2 or
The coronavirus that causes COVID-19 can sometimes hijack brain cells, using the cells’ internal machinery to copy itself, according to a new study. The research, posted Sept. 8 to the preprint database bioRxiv, has not yet been published in a peer-reviewed journal, but it provides evidence that SARS-CoV-2 can directly infect brain cells called neurons. Although
Initially, children were thought to be spared from disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, a month into the epidemic, a novel multisystem inflammatory syndrome in children (MIS-C) emerged. In thi paper on Cell, are reported the immune profiles of nine MIS-C cases. All MIS-C patients had evidence of prior SARS-CoV-2
In this paper on Cell it’s shown that SARS-CoV-2 spike protein interacts with both cellular heparan sulfate and angiotensin converting enzyme 2 (ACE2) through its Receptor Binding Domain (RBD). Docking studies suggest a heparin/heparan sulfate-binding site adjacent to the ACE2 binding site. Both ACE2 and heparin can bind independently to spike protein in vitro and
In a study published in JAMA today, Mount Sinai researchers report findings that shed some light on the disproportionate impact of COVID-19 on Blacks, who have experienced rates of infection and death that are much greater, in some areas twice and three times more, than their proportion of the population. Our study suggests one factor that may
The emergence of adaptive immunity in response to the new Betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), occurs within the first 7 to 10 days of infection. Understanding the key features and the B-cell evolution – and T-cell-mediated adaptive immunity to SARS-CoV-2 is essential to predict the outcomes of coronavirus disease 2019 (COVID-19) and
Mesenchymal stem/stromal cells are not infected by SARS-CoV-2 and retain their immunomodulatory potential as published by Institute for Transfusion Medicine and Immunohaematology, German Red Cross Blood Donor Service in Frankfurt am Main on Stem Cells Report. Previous studies reported safety and applicability of Mesenchymal Stem/Stromal Cells (MSC) to ameliorate pulmonary inflammation in ARDS. Thus, multiple
Researchers at Karolinska Institutet and Science for Life Laboratory in Sweden and Tor Vergata University of Rome in Italy have mapped the immune response in children affected by a rare but life-threatening inflammatory syndrome associated with COVID-19. The study, which is published in the scientific journal Cell, reveals that the inflammatory response differs from that
Multisystem inflammatory syndrome in children (MIS-C), believed to be linked to COVID-19, damages the heart to such an extent that some children will need lifelong monitoring and interventions, said the senior author of a medical literature review. Case studies also show MIS-C can strike seemingly healthy children without warning three or four weeks after asymptomatic
Young adults with underlying conditions such as morbid obesity, diabetes and hypertension are at the highest risk of being placed on a ventilator or dying from COVID-19, according to a study of 3,000 hospitalized patients aged 18 to 34. The analysis, published Wednesday in the journal JAMA Internal Medicine, focused on patients hospitalized between April and
SARS-CoV-2, the virus that causes COVID-19, is entirely new to infectious disease researchers and other public health scientists. To combat it, scientists have sifted through centuries of literature about how the world coped with past pandemics. A new opinion paper assesses one way in which we might be able to learn from our encounters with
People who are admitted to hospital with Covid-19 can be divided into four distinct groups, according to data from the world’s largest study of patients with the disease. Researchers identified the groups using clinical information and tests carried out upon arrival at hospital to predict the patients’ risk of death – ranging from low to
The COVID-19 pandemic is still raging in India, with over 4.5 million cases, 75.000 deaths and more than 90,000 new cases a day. At present there are few effective therapeutic options, which means that healthcare providers are faced with ongoing challenges in managing the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A new study based
The strong pro-inflammatory response known as cytokine storm is said to play an important role in the pathophysiology of a severe variant of covid-19. But researchers at Radboudumc University (Matthijs Kox et al.) doubt that. In a small-scale study published in JAMA, they argue that many studies look at different cytokines and do not make a
One of the features distinguishing SARS-CoV-2 from its more pathogenic counterpart SARS-CoV is the presence of premature stop codons in its ORF3b gene. In this paper it’s shown that SARS-CoV-2 ORF3b is a potent interferon antagonist, suppressing the induction of type I interferon more efficiently than its SARS-CoV ortholog. Phylogenetic analyses and functional assays reveal
Source: The New England Journal of Medicine In a laboratory setting, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was inoculated into human bronchial epithelial cells. This inoculation, which was performed in a biosafety level 3 facility, had a multiplicity of infection (indicating the ratio of virus particles to targeted airway cells) of 3:1. These cells
Dozens of major hospitals across the U.S. are grappling with whether to ignore a federal decision allowing broader emergency use of blood plasma from recovered COVID patients to treat the disease in favor of dedicating their resources to a gold-standard clinical trial that could help settle the science for good. As many as 45 hospitals
